Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology - PubMed (original) (raw)

Review

. 2014 May;69(5):1162-76.

doi: 10.1093/jac/dkt508. Epub 2013 Dec 29.

Affiliations

Review

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology

H Ruth Ashbee et al. J Antimicrob Chemother. 2014 May.

Abstract

The burden of human disease related to medically important fungal pathogens is substantial. An improved understanding of antifungal pharmacology and antifungal pharmacokinetics-pharmacodynamics has resulted in therapeutic drug monitoring (TDM) becoming a valuable adjunct to the routine administration of some antifungal agents. TDM may increase the probability of a successful outcome, prevent drug-related toxicity and potentially prevent the emergence of antifungal drug resistance. Much of the evidence that supports TDM is circumstantial. This document reviews the available literature and provides a series of recommendations for TDM of antifungal agents.

Keywords: fungal diseases; fungal pathogens; triazoles.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53:24–34. - PMC - PubMed
    1. Bruggemann RJ, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit. 2008;30:403–11. - PubMed
    1. Hope WW, Billaud EM, Lestner J, et al. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis. 2008;21:580–6. - PubMed
    1. Lewis RE. Antifungal therapeutic drug monitoring. Curr Fungal Infect Rep. 2010;4:158–67.
    1. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources